It remains unclear whether the imbalanced pharmacology or the longer half-life of tirzepatide contributes to its superior efficacy in glucose and weight reduction compared to the more balanced dual agonist, NNC0090-2746
35 Although these CVOTs were not specifically powered to detect differences in HF outcomes, they provided the first valuable signs of the benefit of GLP-1RAs in patients with HF
Healthspan uses GLP-1s as a longevity and metabolic health toolnot just for weight loss
This is why GLP-1 medications are generally not recommended for individuals with a personal or family history of Medullary Thyroid Cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic condition that predisposes people to certain endocrine tumours
How might impaired renal function affect the clearance, dosing frequency, and efficacy of GLP-1 receptor agonists, such as semaglutide
Figure 27: Photograph of Sir James Black (1924-2010), credit: Lyall
